Abstract
Within the context of drug development in pharmaceutical industry what do we mean by investigative toxicology? We include, among other things, the development of new procedures for assessing toxicity, the investigation of mechanisms of toxicity and the application of mechanism-based screens with the overall goal of enhancing the effectiveness of drug discovery and development. Although investigative toxicology has an important role to play in drug discovery by aiding the selection of compounds for development, through, for example, the study of structure-toxicity relationships, this article will concentrate on the role of investigative toxicology in drug development. Here the principal goals could be stated as assisting rational decision making and improving the risk-benefit assessment process, thus facilitating regulatory review.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Betton GR, Dormer CS, Wells T, Pert P, Price CA and Buckley P (1988) Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol. 16, 288–298
Boiteux-Antoine AF, Magdalou J, Fournel-Gigleux S and Siest G (1989) Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds. Gen. Pharmacol 20, 407–412
Brown, CG, Harland, RF and Atterwill, CK (1987) Increased thyroxine clearance in rats treated with high doses of a histamine H2-antagonist, SKF 93479. Arch. Toxicol., Suppl. 11, 253–256
Burchell B and Coughtrie MWH(1989) UDP-glucuronyltransferases. Pharmacol Ther 43,261–289
Dohler, KD, Wong, CC and Von Zur Muhlen, A (1979) The rat as a model for the study of drug effects on thyroid function: consideration of methodological problems. Pharmac. Ther., 5, 305–318
Eason, CT, Pattison, A, Howells, DD, Spencer, AJ and Bonner, FW (1988a) Assessment of Gastric Antisecretory Effects of Phenoxyisobutyrate Derivatives in the Rat and the Mouse. Scand J Gastroenterol,23, 1063–1071
Eason, CT, Spencer, AJ, Pattison, A, Howells DD, Henry DC and Bonner FW (1988b) Species Variation in Gastric Toxicity following Chronic Administration of Ciprofibrate to Rat,Mouse and Marmoset. Toxicol. Appl. Pharmacol. 95, 328–338
Ekman L, Hansson E, Havu N, Carlsson E and Lundberg C (1985) Toxicology studies on omeprazole. Scand. J. Gastroenterol. 20, 53–69
Harland, WA and Orr, JS (1975) The effect of Clofibrate on thyroxine metabolism. In ’Thyroid Hormone Metabolism’ Ed. W.A. Harland and JS Orr. Academic Press, pp 65–87
Hinton, RH, Mitchell FE, Mann A, Chescoe D, Price SC, Nunn A, Grasso P and Bridges JW (1986) Effects of phthalic esters on the liver and thyroid. Environ Health Perspect 70, 195–210
Hirth RS, Evans LD, Buroker RA and Oleson FB (1988) Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: An indirect effect of the histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 26, 1284–1295
Kaiser CA, Seydoux J, Giacobino JP, Girardier L and Burger AG (1988) Increased plasma clearance rate of thyroxine despite decreased 5’-monodeiodination: study with a peroxisome proliferator in the rat. Endocrinology 122, 1087–1093
Lippman W and Sethaler K (1976) Clofibrate: antisecretory antiulcer activity in the rat. J. Pharm. Pharmac. 23, 165
McClain, MR, Levin AA, Posch, R and Downing JC (1989) The effect of phenobarbital on the metabolism and excretion of thyroxine in rats. Toxicol. Appl. Pharmacol., 99, 216–228
Poynter D, Pick CR, Harcourt RA, Selway SAM, Ainge G, Harman IW, Spurling NW, Fluck PA, and Cook JL (1986a) Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut 26: 1284–1295.
Poynter D, Selway SAM, Papworth SA and Riches SR (1986b) Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockdage. Gut 27, 1338–1346
Price, SC, Chesco, D and Hinton RH (1984) Changes in the colloid and lysosomes of the thyroid of rats treated with Clofibrate. Biochem. Soc. Trans. 12, 1034–1035
Rheault MJ, Laberge M, Lelomer J and Tetreault C (1982) The gastric antisecretory effects of Clofibrate in the rat. Rev. Can. Biol. Exp. 41, 165
Ruegamer, WR, Ryan NT, Richert, DA and Weshenfield, WW (1969) Effect of p-chlorophenoxyisobutyrate on the turnover rate and distribution of thyroid hormone in the rat. Biochem. Pharmacol., 18, 613–624
Streett CS,Robertson JL and Crissman JW (1988) Morphologic stomach findings in rats and mice treated with the H2-receptor antagonist, ICI 125,211 and ICI 162,846. Toxicol. Pathol. 16, 299–304
Svoboda DJ and Azarnoff DL (1979) Tumours in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidaemic drug. Cancer Res. 39, 3419–3428
Westermark, K, Karlsson, FA and Westermark, B (1985) Thyrotropin modulates EGF receptor function in porcine thyroid follicle cells. Mol. Cell. Endocrinol., 40, 17–23
Zbinden, G (1987a) CMR Annual Lecture: Predictive Value of Animal Studies in Toxicology. Published by Centre for Medicines Research
Zbinden, G (1987b) Assessment of hyperplastic and neoplastic lesions of the thyroid gland. TIPS, 8, 511–514
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Harpur, E.S., Bonner, F.W. (1994). The Role of Investigative Toxicology in Pharmaceutical Industry. In: Bolt, H.M., Hellman, B., Dencker, L. (eds) Use of Mechanistic Information in Risk Assessment. Archives of Toxicology, Supplement 16, vol 16. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78640-2_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-78640-2_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78642-6
Online ISBN: 978-3-642-78640-2
eBook Packages: Springer Book Archive